Literature DB >> 12042261

Luteal phase progesterone excretion in ovulatory women with polycystic ovaries.

Rosanne Joseph-Horne1, Helen Mason, Sari Batty, Davinia White, Stephen Hillier, Martha Urquhart, Stephen Franks.   

Abstract

BACKGROUND: Various studies have reported a prevalence of polycystic ovaries (PCO) of approximately 20% in the 'normal' population. Our aim was to investigate the frequency of ovulation and pattern of luteal phase progesterone secretion in a group of women with PCO who reported regular cycles and in whom ovulation had been established on the basis of previous investigations.
METHODS: Subjects collected early morning urine samples for pregnanediol-3-glucuronide measurement from day 10 of the cycle to day 1 of their next menses. Results in three consecutive cycles from women with PCO (group 1, n = 10 and 29 for patients and cycles respectively) were compared with results from two groups with normal ovaries; with either infertility (group 2, n = 10 and 30) or proven fertility (group 3, n = 6 and 19).
RESULTS: There were considerable variations in cycle length. The median (range) was group 1: 28 (23-47); group 2: 26 (21-36) and group 3: 27 (25-38) days with more short cycles in both infertile groups. There was more variation in pregnanediol:creatinine in the normal-ovary infertile and PCO groups than in the fertile controls. Levels were higher in the early luteal phase in the fertile normal group than in either infertile group, and the mid-luteal phase peak was lower in the infertile women with normal ovaries. In summary, there was greater variability in luteal phase pregnanediol:creatinine ratios in the PCO and infertile normal-ovary groups than in women with normal ovaries and proven fertility.
CONCLUSION: Women with PCO did not have more variation in cycle length than fertile women with normal ovaries, but there were significantly lower levels of progesterone in the early luteal phase. This may contribute to the delay in conception in these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042261     DOI: 10.1093/humrep/17.6.1459

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  12 in total

1.  Menstrual cycle, pregnancy and oral contraceptive use alter attraction to apparent health in faces.

Authors:  B C Jones; D I Perrett; A C Little; L Boothroyd; R E Cornwell; D R Feinberg; B P Tiddeman; S Whiten; R M Pitman; S G Hillier; D M Burt; M R Stirrat; M J Law Smith; F R Moore
Journal:  Proc Biol Sci       Date:  2005-02-22       Impact factor: 5.349

2.  Physical properties of alginate hydrogels and their effects on in vitro follicle development.

Authors:  Erin R West; Min Xu; Teresa K Woodruff; Lonnie D Shea
Journal:  Biomaterials       Date:  2007-07-23       Impact factor: 12.479

Review 3.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

4.  Impact of hypocaloric dietary intervention on ovulation in obese women with PCOS.

Authors:  Brittany Y Jarrett; Marla E Lujan
Journal:  Reproduction       Date:  2016-10-31       Impact factor: 3.906

Review 5.  Common pathophysiological mechanisms involved in luteal phase deficiency and polycystic ovary syndrome. Impact on fertility.

Authors:  Georgios Boutzios; Maria Karalaki; Evangelia Zapanti
Journal:  Endocrine       Date:  2012-08-29       Impact factor: 3.633

Review 6.  Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome.

Authors:  Katie Nitsche; David A Ehrmann
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-10       Impact factor: 4.690

7.  Facial appearance is a cue to oestrogen levels in women.

Authors:  M J Law Smith; D I Perrett; B C Jones; R E Cornwell; F R Moore; D R Feinberg; L G Boothroyd; S J Durrani; M R Stirrat; S Whiten; R M Pitman; S G Hillier
Journal:  Proc Biol Sci       Date:  2006-01-22       Impact factor: 5.349

8.  Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys.

Authors:  David H Abbott; Alice F Tarantal; Daniel A Dumesic
Journal:  Am J Primatol       Date:  2009-09       Impact factor: 2.371

9.  Polycystic Ovary Syndrome and Obstructive Sleep Apnea.

Authors:  Esra Tasali; Eve Van Cauter; David A Ehrmann
Journal:  Sleep Med Clin       Date:  2008-03

10.  Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys.

Authors:  Rao Zhou; Cristin M Bruns; Ian M Bird; Joseph W Kemnitz; Theodore L Goodfriend; Daniel A Dumesic; David H Abbott
Journal:  Reprod Toxicol       Date:  2007-01-14       Impact factor: 3.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.